463
Participants
Start Date
August 31, 2013
Primary Completion Date
December 31, 2015
Study Completion Date
February 29, 2016
PEG-Tα1
3.2mg/ml, once a week, taken subcutaneously
Placebo to match PEG-Tα1
1ml, once a week, taken subcutaneously
Adefovir
10 mg, once daily, taken orally for 48 weeks
302 Military Hoapital of China, Beijing
Beijing YouAn Hospital, Capital Medical University, Beijing
Southwest Hospital, Chongqing
The First Affiliated Hospital of Chongqing Medical University, Chongqing
The First Hospital of Lanzhou University, Lanzhou
Shenzhen People's Hospital, Shenzhen
Hainan General Hospital, Haikou
The First Hospital of Hebei Medical University, Shijiazhuang
The Third Hospital of Hebei Medical University, Shijiazhuang
People's Hospital of Wuhan University, Wuhan
Zhongshan Hospital of Hubei Province, Wuhan
The Second Xiangya Hospital of Central South University, Changsha
The Third Xiangya Hospital of Central South University, Changsha
The First Affiliated Hospital of South China University, Hengyang
81 Military Hospital of China, Nanjing
Jiangsu Province Hospital, Nanjing
The Second Hospital of Nanjing, Nanjing
The Affiliated Hospital of Xuzhou Medical College, Xuzhou
The First Hospital of Jilin University, Changchun
Yanbian University Hospital, Yanbian
The Sixth People's Hospital of Shenyang, Shenyang
Jinan Infectious Disease Hospital, Jinan
Qilu Hospital of Shandong University, Jinan
The Six People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai
Tangdu Hospital, Xi’an
The First Affiliated Hospital of Xi'an Jiaotong University, Xi’an
The Second Affiliated Hospital of Xi'an Jiaotong University, Xi’an
Xijing Hospital, Xi’an
West China Hospital Sichuan University, Chengdu
Tianjin Second People's Hospital, Tianjin
XiXi Hospital of Hangzhou, Hangzhou
Taizhou Hospital of Zhejiang Province, Taizhou
Lead Sponsor
Collaborators (1)
Nanjing Medical University
OTHER
Jiangsu Hansoh Pharmaceutical Co., Ltd.
INDUSTRY